# ZNF839

## Overview
ZNF839 is a gene that encodes the zinc finger protein 839, which is a member of the zinc finger protein family known for their role in DNA binding and transcriptional regulation. Zinc finger protein 839 functions primarily as a co-transcription factor, interacting with the transcription factor Runx2 to enhance the transcription of genes critical for osteoblast differentiation and bone formation. This protein is predominantly active in the nucleus, where it plays a significant role in the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) by promoting the expression of osteoblast-specific genes. The translation of ZNF839 mRNA is regulated by the m6A 'reader' protein YTHDF1, which binds to the mRNA in an m6A-dependent manner, ensuring appropriate protein levels for effective osteogenesis (Liu2021The). ZNF839 has also been implicated in various clinical conditions, including osteoporosis, amyotrophic lateral sclerosis (ALS), peripheral artery disease (PAD), and clear cell renal cell carcinoma, highlighting its diverse physiological and pathological roles (Machiraju2024Paired; Takahashi2016Downregulation; Zhang2024Deep).

## Function
ZNF839, a zinc finger protein, plays a significant role in the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). It functions as a co-activator of the transcription factor Runx2, which is crucial for osteoblast differentiation. ZNF839 enhances the transcriptional activity of Runx2, thereby promoting the expression of osteoblast-specific genes such as Alp, Osterix, and Ocn, which are essential for bone formation and remodeling (Liu2021The).

The activity of ZNF839 is regulated post-transcriptionally by the m6A 'reader' protein YTHDF1. YTHDF1 binds to ZNF839 mRNA and promotes its translation in an m6A-dependent manner, particularly near the translation stop codon. This regulation is crucial for maintaining appropriate protein levels of ZNF839, which in turn influences BMSC osteogenesis (Liu2021The).

ZNF839 is primarily active in the nucleus, where it interacts with Runx2 to form a regulatory complex that enhances the transcription of osteogenic-specific genes. This interaction suggests that ZNF839 functions as a co-transcription factor, modulating the activity of Runx2 rather than its expression (Liu2021The).

## Clinical Significance
Alterations in the expression of the ZNF839 gene have been implicated in several diseases. In the context of bone metabolism, ZNF839 is crucial for the osteogenesis of bone marrow mesenchymal stem cells (BMSCs). The m6A 'reader' protein YTHDF1 promotes the translation of ZNF839, which acts as a co-activator of the transcription factor Runx2, essential for osteoblast differentiation. Deletion of YTHDF1, which leads to reduced ZNF839 expression, results in low bone mass, suggesting a role in conditions like osteoporosis (Liu2021The).

In amyotrophic lateral sclerosis (ALS), lower expression levels of ZNF839 are associated with a faster disease progression and shorter survival time. Specific noncoding genetic variants linked to ZNF839 have been identified, with carriers showing a shorter mean survival time, indicating its potential role in ALS progression (Zhang2024Deep).

ZNF839 is also upregulated in peripheral artery disease (PAD), where it is among the top genes with increased expression in atheromatous vessels, suggesting a role in the disease's inflammatory processes (Machiraju2024Paired). Additionally, ZNF839 is downregulated in clear cell renal cell carcinoma due to the loss of chromosome 14q, although its specific role in this cancer type is less clear (Takahashi2016Downregulation).

## Interactions
ZNF839, a zinc finger protein, is involved in several interactions that are crucial for its function in osteogenesis. It interacts with the transcription factor Runx2, a key regulator in the differentiation of bone marrow mesenchymal stem cells (BMSCs) into osteoblasts. This interaction enhances the transcriptional activity of Runx2, promoting the expression of osteoblast-specific genes such as Alp, Osterix, and Ocn. The interaction between ZNF839 and Runx2 has been confirmed through immunoprecipitation experiments and luciferase assays, which demonstrate increased activity of osteogenic-specific gene promoters when ZNF839 is present (Liu2021The).

ZNF839 is also regulated post-transcriptionally by the m6A 'reader' YTHDF1. YTHDF1 binds to ZNF839 mRNA in an m6A-dependent manner, enhancing its translation without significantly altering mRNA levels. This regulation is crucial for the osteogenic potential of BMSCs, as YTHDF1 knockdown leads to reduced osteogenesis (Liu2021The). These interactions highlight the role of ZNF839 in the regulatory network of bone metabolism and its potential involvement in other physiological processes.


## References


1. (Machiraju2024Paired) Paired transcriptomic analyses of atheromatous and control vessels reveal novel autophagy and immunoregulatory genes in peripheral artery disease. This article has 0 citations.

[2. (Takahashi2016Downregulation) Mika Takahashi, Yoshiyuki Tsukamoto, Tomoki Kai, Akinori Tokunaga, Chisato Nakada, Naoki Hijiya, Tomohisa Uchida, Tsutomu Daa, Takeo Nomura, Fuminori Sato, Hiromitsu Mimata, Keiko Matsuura, and Masatsugu Moriyama. Downregulation of <scp>wdr</scp>20 due to loss of 14q is involved in the malignant transformation of clear cell renal cell carcinoma. Cancer Science, 107(4):417–423, March 2016. URL: http://dx.doi.org/10.1111/cas.12892, doi:10.1111/cas.12892. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/cas.12892)

[3. (Liu2021The) Tao Liu, Xinfeng Zheng, Chenglong Wang, Chuandong Wang, Shengdan Jiang, Bo Li, Pengbo Chen, Wenning Xu, Huoliang Zheng, Runze Yang, Xingxu Huang, Xiaoling Zhang, and Leisheng Jiang. The m6a “reader” ythdf1 promotes osteogenesis of bone marrow mesenchymal stem cells through translational control of znf839. Cell Death &amp; Disease, November 2021. URL: http://dx.doi.org/10.1038/s41419-021-04312-4, doi:10.1038/s41419-021-04312-4. This article has 32 citations.](https://doi.org/10.1038/s41419-021-04312-4)

4. (Zhang2024Deep) Deep learning modeling of rare noncoding genetic variants in human motor neurons definesCCDC146as a therapeutic target for ALS. This article has 0 citations.